Budget Impact of Vericiguat for Treating Chronic Heart Failure in Japan.

ABSTRACT:

Background

Chronic heart failure (CHF) affects millions worldwide, posing a significant burden on healthcare resources. For patients with HF with reduced ejection fraction (HFrEF) following a worsening event, vericiguat is a promising new treatment. In this study we evaluated the budgetary impact on Japan's health system with the introduction of vericiguat as an add-on to standard of care (SoC) for chronic HFrEF after a worsening event.

Methods and results

An economic model was developed comparing SoC to a scenario in which vericiguat is introduced as an add-on therapy over a 5-year time horizon. A literature review, medical claims data and clinical trial data were used to derive inputs. Total healthcare costs after introducing vericiguat were estimated to increase <1% over

SUBMITTER: Kuwahara K 

PROVIDER: S-EPMC12688427 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature